RemeGen Co., Ltd. (SHA:688331)

Market Cap	49.49B +328.1%
Revenue (ttm)	2.23B +46.3%
Net Income	-947.63M
EPS	-1.75
Shares Out	n/a
PE Ratio	n/a
Forward PE	139.96
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,249,949
Average Volume	7,967,217
Open	99.51
Previous Close	100.20
Day's Range	97.73 - 103.33
52-Week Range	27.22 - 118.88
Beta	0.74
RSI	52.41
Earnings Date	Mar 28, 2026

About RemeGen

RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of various cancers. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial gro...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 3,070
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688331

Financial Performance

In 2024, RemeGen's revenue was 1.72 billion, an increase of 58.54% compared to the previous year's 1.08 billion. Losses were -1.47 billion, -2.84% less than in 2023.